Test Price
3,200 AED✅ Home Collection Available
OncoPro Prostate Cancer Screening Test in UAE | 3200 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
- Clinical Guidance: Free telephonic post-test result interpretation by our expert team.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
- Turnaround Time: 21 Working Days from sample receipt at laboratory.
- Regulatory Compliance: Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
Overview
The OncoPro Prostate Cancer Screening Test is a liquid biopsy that detects circulating tumor cells (CTCs) using advanced extraction and multi‑parameter immunostaining, providing superior risk stratification for prostate cancer far beyond standard PSA measurements. This molecular-level assay captures malignant cells shed directly from the prostate, delivering exceptional specificity and reducing unnecessary invasive procedures.
Methodology Comparison
| Feature | Our OncoPro Test | Standard PSA Test |
|---|---|---|
| Methodology | Circulating tumor cell extraction & specialized immunostaining | Immunoassay for prostate‑specific antigen |
| Clinical Precision | Molecular‑level risk profiling, 99.9% sensitivity | Elevated PSA alone; lower specificity |
| Turnaround Time | 21 Working Days | 1–2 Days |
| Price | 3200 AED | ~150–300 AED |
Physician Insight & Safety Protocols
“The OncoPro liquid biopsy represents a significant advancement in prostate cancer risk stratification. By directly capturing circulating tumor cells, it offers markedly improved specificity compared to conventional PSA screening. However, clinicians must interpret any abnormal result within the full clinical context — a confirmatory urological evaluation and cross-sectional imaging remain essential before proceeding to biopsy or treatment decisions. This test is a powerful screening adjunct, not a standalone diagnostic endpoint.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Critical Medication Advisory
Do not discontinue any prescribed medication, including anticoagulants, hormonal therapy, or alpha‑blockers, without prior consultation with your treating physician. Abrupt cessation may lead to adverse cardiovascular or thromboembolic events.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide 8 mL of whole blood; hemolyzed or clotted specimen; active febrile illness; incomplete OncoPro Clinical Information Form (Form 30).
- Emergency Red Flags – Seek Immediate Care: Sudden inability to urinate, severe bone pain, new‑onset leg weakness or numbness, unexplained weight loss, or visible blood in urine.
All clinical procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient safety and informed consent standards.
Patient FAQ & Clinical Guidance
1. How does the OncoPro test differ from a standard PSA blood test?
OncoPro test detects prostate circulating tumor cells with higher cancer‑specific accuracy than PSA testing alone.
A standard PSA test measures a protein that can be elevated in benign conditions like prostatitis or BPH, leading to false positives. OncoPro directly captures malignant cells shed from the prostate, providing a more specific risk assessment and reducing unnecessary biopsies.
2. What are the sample collection requirements for the OncoPro test?
Draw 8 mL whole blood into lavender‑top EDTA tube, mix with preservative, transport at room temperature.
Use the kit provided, add the preservative using a sterile syringe and needle. The sample must be shipped immediately at 18–22°C — do not refrigerate or freeze. A duly completed OncoPro Clinical Information Form (Form 30) is mandatory for processing.
3. Is the OncoPro covered by UAE health insurance?
UAE insurers often cover OncoPro screening with pre‑approval; we handle direct billing checks via WhatsApp.
Coverage varies by plan and clinical necessity. Our patient support team verifies your benefits and obtains prior authorization for seamless direct billing. Contact us on +971 54 548 8731 to confirm your coverage before sample collection.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License 1143 and adheres strictly to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, access-controlled, and processed in compliance with UAE data sovereignty requirements.
Clinical & Logistical Metadata
| Test Name | OncoPro Prostate Cancer Screening Test |
| Price (AED) | 3200 AED |
| Turnaround Time | 21 Working Days |
| Sample Type / Matrix | Whole blood (8 mL) in EDTA tube |
| Methodology Used | Circulating tumor cell extraction and multi‑parameter immunostaining |
| ICD-10-CM Code | Z12.5 — Encounter for screening for malignant neoplasm of prostate |
| LOINC Code | 85309-6 — Circulating tumor cells [Presence] in Blood |
| DHA Facility License & Laboratory Address Invariants | License: 1143 | Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians